The story, briefly
For most of its life as a public company, Indivior earned almost nothing, carried litigation like ballast, and traded at a multiple that reflected hope rather than results. The filings now show something different: a business generating real margins from a single dominant drug, with earnings that have turned sharply positive. Our data puts the current price-to-earnings multiple at 19.5, sitting at just the 9th percentile of its own decade-long range, meaning the stock is priced far cheaper relative to earnings than it has been almost any time in its history. The open question is whether the market’s caution reflects durable risks, litigation, pipeline concentration, deal uncertainty, or whether the multiple will eventually reflect the margin transformation. Both readings have evidence behind them.
A company that spent a decade becoming itself
Indivior was spun out of Reckitt Benckiser in December 2014, built almost entirely around Suboxone Film, a dissolvable strip used to treat opioid addiction. For years, that was both the asset and the liability. The drug generated strong annual sales, but a court eventually cleared the way for generic competition and the revenue base began to erode. Simultaneously, the company was fighting a cascade of legal battles over how it had marketed its products, culminating in a series of large settlements for false marketing claims, civil obligations with states, and antitrust exposure that stretched across nearly a decade.
The saving grace was a drug that had been approved quietly in the background. The FDA cleared SUBLOCADE, a once-monthly injectable form of buprenorphine for opioid use disorder, in November 2017. Unlike the film, it can’t be diverted or misused easily, which made it attractive to clinicians and payers alike. It took years to build the market. Then it started to run.
What the filings actually show
The 10-K for fiscal year 2025 shows that SUBLOCADE now generates roughly seven of every ten revenue dollars the company collects. Net margin for the year came in at 16.9%, a figure that matters because as recently as fiscal 2024 the same margin was essentially zero, per the prior year’s 10-K. That is not a gradual improvement. That is a business crossing a threshold.
The most recent quarter extends the story. The 10-Q for the quarter ended June 30, 2026 shows total net revenue up double digits from the same quarter a year earlier, with SUBLOCADE growing even faster. The adjusted EBITDA margin, how many cents of operating profit the company keeps from each dollar of sales before interest and taxes, nearly doubled year-over-year. That kind of margin expansion, in a single year, is unusual in any industry.
Indivior’s CFO Ryan Preblick, in the Q2 2026 earnings release, attributed the improvement to a simplified operating model and cost discipline. The company raised its full-year 2026 guidance to revenue of $1.295 billion to $1.365 billion and adjusted EBITDA of $700 million to $740 million.
Where the multiple sits in its own history
Here is the contrast that opens this story. Indivior’s current price-to-earnings ratio, the price a buyer pays per dollar of annual profit, sits at 19.5, according to our data. The median P/E across the company’s own decade of trading history is 822. That number is not a typo: for most of Indivior’s public life, the company earned so little that the ratio was either astronomical or meaningless, because the denominator was near zero. Now that earnings are real, the ratio has collapsed to its 9th percentile, meaning the stock has traded at a lower P/E than this only 9% of the time in its own history.
The price-to-sales ratio, which compares the stock’s market value to annual revenue and doesn’t depend on profitability, tells a calmer story. At a reading slightly above its decade median, it sits around the 61st percentile, roughly in line with history. The market is not ignoring the revenue growth. It is, by this lens, paying a fair price for the sales. What it is not currently pricing, by this lens, is the margin transformation, whether that gap closes, persists, or reflects a risk the P/S ratio does not capture is the central analytical question.
What the mood is discounting
Three things explain why the market might be cautious even as the math improves. First, the litigation shadow has not fully lifted. Indivior paid a substantial Department of Justice obligation in January 2026, per the company’s FY 2026 guidance update. The Suboxone tooth decay multidistrict litigation had grown to nearly 18,000 served federal lawsuits as of August 2026, per the Lawsuit Information Center, with bellwether trials not expected until March 2028. The total exposure is genuinely hard to size.
Second, the pipeline has narrowed sharply. In early 2026, Indivior announced it would not pursue Phase 3 development for INDV-6001 (a Q1 2026 decision) and would not advance INDV-2000 internally, leaving SUBLOCADE as essentially the entire business. A company with one product and a litigation tail carries concentrated exposure, and the market’s valuation appears to reflect that concentration.
Third, a proposed merger with Supernus Pharmaceuticals, disclosed in the Q2 2026 earnings release, introduces deal risk. Mergers of this kind carry integration uncertainty, and investors often wait for clarity before re-rating a stock upward. Zacks Investment Research, writing in June 2026, flagged “margin durability” as the key question, noting that gross-to-net adjustments, the discounts and rebates that reduce the headline price a drug company receives, could act as a drag on both SUBLOCADE and SUBOXONE revenue even as reported margins look strong.
As of early August 2026, sell-side coverage of Indivior included at least one bullish rating and a range of price targets, per Benzinga’s analyst rating tracker and Tickernerd’s aggregation of consensus price targets from the four covering firms; those figures represent the attributed views of the named firms and are noted here solely as a record of third-party coverage, not as a BullScope assessment or endorsement of any directional view.
The real-world evidence for SUBLOCADE continues to accumulate. Studies presented at the ASAM Annual Conference in April 2026 and published in peer-reviewed journals through the spring showed that patients who stayed on the monthly injectable had lower relapse rates, fewer hospitalizations, and lower total healthcare costs, per Indivior’s April 2026 release. That kind of evidence builds the clinical and payer case for the drug over time, but it doesn’t resolve the litigation or the pipeline question in the near term.
Reading the numbers
- Net margin: 0.2% (FY2024) vs. 16.9% (FY2025). This is what the company keeps from each dollar of sales after every expense, including taxes. In 2024, Indivior kept less than a penny per dollar. In 2025, it kept about seventeen cents. A household analogy: if a family earned $100,000 and spent $99,800 in one year, then kept $16,900 the next, that is the scale of the shift. Filed in the FY2025 10-K.
- Adjusted EBITDA margin: 54% in Q2 2026. EBITDA (earnings before interest, taxes, depreciation, and amortization) strips out financing and accounting charges to show operating cash generation. A 54% margin means that for every dollar of revenue, 54 cents flows through to operating profit before those items. For a pharmaceutical company selling a single branded drug, that is a high-quality margin. Filed in the Q2 2026 10-Q.
- P/E at the 9th percentile of its own decade. Our data shows the current P/E of 19.5 sits lower than 91% of historical readings. This is not because the stock is cheap on an absolute basis, but because earnings have only recently become real. The ratio is low relative to history because the history was dominated by near-zero earnings. The meaning: the market is applying a modest multiple to a business that has just, for the first time, demonstrated it can earn consistently.
- Litigation: ~18,000 federal lawsuits in the tooth decay MDL. Per-case settlement values in comparable pharmaceutical MDLs have varied widely; any aggregate exposure estimate is speculative without a disclosed reserve figure from the company. The company held $249 million in cash and investments as of June 30, 2026, per the Q2 2026 10-Q, a data point readers can weigh against whatever exposure range they find credible.
Sources
- Indivior 10-Q, Q2 2026 (SEC EDGAR)
- Indivior 10-K, FY2025 (SEC EDGAR)
- Indivior 10-K, FY2024 (SEC EDGAR)
- Indivior Q2 2026 earnings release (GlobeNewswire)
- Indivior FY2026 guidance update
- Zacks Investment Research, June 2026 (TradingView)
- Indivior analyst ratings (Benzinga)
- Indivior consensus forecast (Tickernerd)
- Suboxone tooth decay MDL tracker (Lawsuit Information Center)
- Indivior ASAM 2026 real-world data release (GlobeNewswire)
